Drug · CHEMBL3137343

PEMBROLIZUMAB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. PEMBROLIZUMAB. Drugs and targets, record CHEMBL3137343. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3137343

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: PEMBROLIZUMAB; ChEMBL
ChEMBL ID: CHEMBL3137343; ChEMBL
Type: Antibody; ChEMBL
Brand names: Keytruda, Pembrolizumab component of mk 7684a, Pembrolizumab component of mk-1308a; ChEMBL
Other names: Lambrolizumab, MK-3475, PEMBROLIZUMAB COMPONENT OF KEYLYNK-010, SCH-900475; ChEMBL
Open Targets' highest stage: Approval, for 9 of its 261 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
PDCD1	Programmed cell death protein 1	Programmed cell death protein 1 inhibitor	INHIBITOR	https://conductscience.org/library/genes/5133

Source ChEMBL

Diseases261

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
non-small cell lung carcinoma	Approval	EMA Human Drugs	456	455	https://conductscience.org/library/drugs?q=MONDO_0005233
melanoma	Approval	EMA Human Drugs, PMDA and TTD	233	229	https://conductscience.org/library/drugs?q=MONDO_0005105
head and neck squamous cell carcinoma	Approval	EMA Human Drugs	198	197	https://conductscience.org/library/drugs?q=MONDO_0010150
breast cancer	Phase 3	ClinicalTrials.gov and TTD	152	151	https://conductscience.org/library/drugs?q=MONDO_0007254
colorectal cancer	Phase 3	ClinicalTrials.gov and TTD	101	100	https://conductscience.org/library/drugs?q=MONDO_0005575
triple-negative breast carcinoma	Phase 3	ClinicalTrials.gov	90	90	https://conductscience.org/library/drugs?q=MONDO_0005494
renal cell carcinoma	Approval	EMA Human Drugs	78	76	https://conductscience.org/library/drugs?q=MONDO_0005086
hepatocellular carcinoma	Phase 3	ClinicalTrials.gov and TTD	71	70	https://conductscience.org/library/drugs?q=MONDO_0007256
ovarian cancer	Phase 3	ClinicalTrials.gov	67	66	https://conductscience.org/library/drugs?q=MONDO_0008170
cancer	Phase 3	ClinicalTrials.gov	58	58	https://conductscience.org/library/drugs?q=MONDO_0004992

1 to 10 of 261Source Open Targets

See all 261 diseases

Trials2,518

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 16 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT05665595	A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)	Phase 3	1,594	2025-04-06	pembrolizumab	Its name	ClinicalTrials.gov
NCT03675737	Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)	Phase 3	1,579	2023-10-12	pembrolizumab	Its name	ClinicalTrials.gov
NCT03740165	Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)	Phase 3	1,367	2025-09-12	pembrolizumab	Its name	ClinicalTrials.gov
NCT02506153	Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	Phase 3	1,301	2024-08-27	pembrolizumab	Its name	ClinicalTrials.gov
NCT02220894	Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)	Phase 3	1,274	2019-03-15	pembrolizumab	Its name	ClinicalTrials.gov
NCT04738487	Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	Phase 3	1,264	2025-08-26	pembrolizumab	Its name	ClinicalTrials.gov
NCT01295827	Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)	Phase 1	1,260	2019-12-13	pembrolizumab	Its name	ClinicalTrials.gov
NCT04191096	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)	Phase 3	1,251	2023-11-18	pembrolizumab	Its name	ClinicalTrials.gov
NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	Phase 3	1,244	2023-12-20	pembrolizumab	Its name	ClinicalTrials.gov
NCT02504372	Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)	Phase 3	1,177	2024-02-15	pembrolizumab	Its name	ClinicalTrials.gov

1 to 10 of 2,518

See all 2,518 trials

Comparisons in its trials730

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause	364 of 618	3,780 of 4,661	5,279	NCT05834348	Trial comparisons
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)	267 of 785	206 of 787	1,572	NCT03675737	Trial comparisons
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE)	776 of 785	771 of 787	1,572	NCT03675737	Trial comparisons
Pembrolizumab/Vibostolimab vs Pembrolizumab: deaths from any cause	6 of 701	1 of 701	1,402	NCT05665595	Trial comparisons
Pembrolizumab/Vibostolimab vs Pembrolizumab: serious adverse events	109 of 698	57 of 700	1,398	NCT05665595	Trial comparisons
FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause	130 of 654	131 of 647	1,301	NCT02506153	Trial comparisons
Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)	126 of 636	93 of 615	1,251	NCT02220894	Trial comparisons
Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Experienced At Least One Adverse Event (AE)	608 of 636	606 of 615	1,251	NCT02220894	Trial comparisons
Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: deaths from any cause	105 of 626	93 of 625	1,251	NCT04191096	Trial comparisons
Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: serious adverse events	252 of 625	145 of 625	1,250	NCT04191096	Trial comparisons

1 to 10 of 730

See all 730 comparisons in its trials

Papers from its trials1,507

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42927856	RESULT	1	PubMed
41747221	RESULT	1	PubMed
41520892	RESULT	1	PubMed
41405563	RESULT	1	PubMed
41315371	RESULT	1	PubMed
41315271	RESULT	1	PubMed
41135379	RESULT	1	PubMed
41115468	RESULT	1	PubMed
40885529	RESULT	1	PubMed
40819431	RESULT	1	PubMed

1 to 10 of 1,507

See all 1,507 papers from its trials

Tests in its trials1

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome
Go/No-Go Task	1	1

Source ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL3137343

GET https://conductscience.org/api/drugs/v1/CHEMBL3137343/diseases?page=2

API reference For AI assistants